TPI-287 (Abeotaxane)
Recurrent Glioblastoma, Neuroblastoma, Medulloblastoma, Refractory Prostate Cancer, Tauopathy Disease (Dementia)
Phase 2Legacy Program - Exploring Out-licensing
Key Facts
Indication
Recurrent Glioblastoma, Neuroblastoma, Medulloblastoma, Refractory Prostate Cancer, Tauopathy Disease (Dementia)
Phase
Phase 2
Status
Legacy Program - Exploring Out-licensing
Company
About CNS Pharmaceuticals
CNS Pharmaceuticals is a biotech firm executing a disciplined, data-driven strategy to identify and develop differentiated therapies for serious neurological and oncological diseases with significant unmet needs. Led by an experienced executive team with decades of industry expertise, the company is focused on acquiring or in-licensing promising assets to build a new pipeline. Its legacy programs, including the blood-brain barrier permeable abeotaxane TPI-287, are being explored for out-licensing to align resources with the new strategic direction.
View full company profile